By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



3334 East Coast Hwy 157

Corona del Mar  California  92625  U.S.A.
Phone: 949-721-4063 Fax: 949-760-1030



Company News
CureDuchenne’s Funding Bears Fruit With Drisapersen: First-Ever New Drug Application (NDA) Accepted By FDA For Duchenne Muscular Dystrophy 6/29/2015 10:44:49 AM
Capricor Therapeutics, Inc. And CureDuchenne To Host Webinar On June 19, 2015 At 3:00 P.M. ET 6/15/2015 2:12:22 PM
CureDuchenne Celebrates Submission Of First-Ever New Drug Application For Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping; Cureduchenne Was Early Funder Of Drisapersen’s Development 4/27/2015 10:26:31 AM
Capricor Therapeutics, Inc. And CureDuchenne To Host Webinar On January 21, 2015 At 3:00 P.M. ET 1/21/2015 7:40:59 AM
CureDuchenne Seeds Collaborative Project To Analyze The Natural History Of Duchenne Muscular Dystrophy 1/13/2015 7:35:57 AM
ProSensa Holding N.V. (RNA) And CureDuchenne Strengthen Long-Term Collaboration With An Additional [Eur]5M To Advance DMD Pipeline 8/11/2014 4:28:22 PM
CureDuchenne Media Statement Regarding ProSensa Holding N.V. (RNA) Announcement Of Regulatory Path Forward For Drisapersen As A Potential Treatment For DMD 6/3/2014 10:01:49 AM
CureDuchenne Release: “CureDuchenne Ventures” Launched to Accelerate Drug Discovery and Development for Duchenne Muscular Dystrophy 9/26/2013 9:58:01 AM
CureDuchenne to Host Drug Development and Clinical Trial Participation – A Webinar for the Rare Disease Community on September 13 9/10/2013 6:48:51 AM
Statement From CureDuchenne Regarding ProSensa B.V. IPO 6/28/2013 9:31:59 AM